Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled time : 22:15 save search
Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma
Published: 2020-06-22 (Crawled : 22:15) - globenewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
|
| O: 3.79%
H: 6.33%
C: 2.38%
treatment phase 3 phase 1 phase 2 nivolumab
Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
Published: 2020-05-27 (Crawled : 22:15) - globenewswire.com
CRBP | $36.53 -1.7% -1.91% 130K
|
Health Technology
|
| O: 1.25%
H: 0.99%
C: -5.18%
sclerosis phase 3 treatment
Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
Published: 2020-06-22 (Crawled : 22:15) - globenewswire.com
CRBP | $36.53 -1.7% -1.91% 130K
|
Health Technology
|
| O: 1.43%
H: 2.25%
C: 0.64%
treatment phase 2b fibrosis cystic fibrosis
Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
Published: 2020-08-05 (Crawled : 22:15) - globenewswire.com
CRBP | $36.53 -1.7% -1.91% 130K
|
Health Technology
|
| O: 1.31%
H: 4.89%
C: 2.88%
phase 3 treatment enroll
Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
Published: 2020-09-08 (Crawled : 22:15) - globenewswire.com
CRBP | $36.53 -1.7% -1.91% 130K
|
Health Technology
|
| O: -75.89%
H: 9.87%
C: 0.0%
results sclerosis phase 3 treatment topline
Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint
Published: 2020-10-06 (Crawled : 22:15) - globenewswire.com
CRBP | $36.53 -1.7% -1.91% 130K
|
Health Technology
|
| O: -41.27%
H: 15.32%
C: 9.01%
treatment phase 2b fibrosis cystic fibrosis
Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
Published: 2020-06-01 (Crawled : 22:15) - globenewswire.com
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
| Email alert
Add to watchlist
fda drug new drug treatment application
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.